L-Carnitine
Weight LossPreclinicalAlso known as: Carnitine, LCAR
L-Carnitine is a naturally occurring quaternary ammonium compound synthesized in the body from the amino acids lysine and methionine, with essential cofactor roles in fatty acid metabolism, energy production, and cellular health. Chemically classified as a conditionally essential nutrient, it is stored primarily in skeletal muscle (about 95% of total body carnitine, roughly 20 grams in an adult), with smaller pools in the liver, brain, heart, kidneys, and sperm.
Overview
At A Glance
L-Carnitine's mechanisms extend beyond the simple "fat-burning nutrient" label. Understanding these mechanisms helps predict where supplementation will and will not produce meaningful effects.…
Mechanism of Action
L-Carnitine's mechanisms extend beyond the simple "fat-burning nutrient" label. Understanding these mechanisms helps predict where supplementation will and will not produce meaningful effects.
The carnitine shuttle — core mechanism. The fundamental role of L-carnitine is transporting long-chain fatty acids across the inner mitochondrial membrane. The process involves three enzymes: carnitine palmitoyltransferase 1 (CPT1) on the outer mitochondrial membrane, carnitine-acylcarnitine translocase (CACT) on the inner membrane, and CPT2 on the matrix side. Long-chain fatty acyl-CoA cannot cross the inner membrane; CPT1 attaches carnitine to form long-chain acylcarnitine, which CACT transports into the matrix, where CPT2 removes the carnitine and regenerates the fatty acyl-CoA for beta-oxidation. Free carnitine then returns to the cytosol via CACT. This shuttle is rate-limiting for fatty acid oxidation in most tissues (Longo et al., 2016).
Implications of the carnitine shuttle. Because CPT1 can be inhibited by malonyl-CoA (an intermediate of fatty acid synthesis), the carnitine shuttle is regulated by cellular metabolic state. When energy supply is ample (fed state, high insulin), malonyl-CoA is high and CPT1 is inhibited — fatty acid oxidation is suppressed. During fasting, exercise, or carbohydrate restriction, malonyl-CoA drops and CPT1 activity increases, allowing fatty acid oxidation to proceed. L-Carnitine supplementation cannot override this regulation — adding more carnitine to a fed, carbohydrate-replete state will not meaningfully increase fat oxidation. This is why L-carnitine is often disappointing as a "fat burner" when taken without appropriate metabolic context (fasted cardio, carbohydrate-restricted diet, active caloric deficit).
Acetyl-CoA buffering (acetylcarnitine). Beyond fatty acid transport, carnitine also buffers the mitochondrial acetyl-CoA pool through conversion to acetylcarnitine (which ALCAR supplementation directly provides). When mitochondria are producing acetyl-CoA faster than the TCA cycle can consume it (e.g., during intense exercise, or with rapid fatty acid oxidation), the excess acetyl-CoA is transferred to carnitine to form acetylcarnitine. This prevents acetyl-CoA accumulation, which would otherwise inhibit pyruvate dehydrogenase and impair glucose oxidation. This mechanism helps explain how L-carnitine can improve metabolic flexibility — the ability to switch between fat and carbohydrate oxidation based on substrate availability (Stephens et al., 2007).
Blood-brain barrier penetration and CNS effects (ALCAR). Plain L-carnitine crosses the blood-brain barrier poorly. Acetyl-L-carnitine (ALCAR) penetrates the BBB more effectively and also serves as an acetyl donor for synthesis of acetylcholine — a key neurotransmitter for memory and cognitive function. ALCAR supports neuronal energy metabolism, mitochondrial function in neurons, and NGF (nerve growth factor) responsiveness. It upregulates the expression of heat shock proteins, reduces oxidative damage in aging neurons, and supports myelin integrity. These CNS mechanisms underpin ALCAR's evidence in cognitive aging, Alzheimer's disease, and peripheral neuropathy (Traina, 2016).
Mitochondrial biogenesis and function. L-Carnitine supports mitochondrial biogenesis through multiple pathways including PGC-1alpha upregulation (the master regulator of mitochondrial biogenesis), improved mitochondrial membrane potential maintenance, and protection of mitochondrial DNA from oxidative damage. These effects contribute to the general "mitochondrial support" narrative around carnitine — particularly relevant in aging, where mitochondrial dysfunction is central to the aging phenotype.
Endothelial function and nitric oxide. Propionyl-L-carnitine (PLC) specifically enhances endothelial nitric oxide synthase (eNOS) activity and supports vascular endothelial function. This underlies its use in peripheral artery disease and in cardiovascular applications where vascular endothelial dysfunction is central. The mechanism is separate from the mitochondrial energy functions of other carnitine forms (Hiatt et al., 2011).
Detoxification of acyl groups. Carnitine can accept acyl groups from a variety of metabolites, serving as a "metabolic sink" for accumulated acyl-CoAs. This is particularly relevant in inborn errors of fatty acid oxidation — many of these conditions result in accumulation of toxic acyl-CoA species, and carnitine supplementation helps "flush" these as acylcarnitines that can be excreted. This is the mechanism by which carnitine is used in medium-chain acyl-CoA dehydrogenase deficiency, very-long-chain acyl-CoA dehydrogenase deficiency, and related disorders.
Muscle carnitine pool and exercise performance. Skeletal muscle contains approximately 95% of total body carnitine, largely as free carnitine with smaller pools of acetylcarnitine and long-chain acylcarnitine. Exercise shifts these pools — prolonged exercise depletes muscle carnitine and shifts the ratio toward acetylcarnitine as fatty acid oxidation intensifies. Insulin-stimulated carnitine uptake via the OCTN2 transporter can increase muscle carnitine levels. This is the basis for the carnitine-with-carbohydrate strategy: co-ingesting carnitine with carbohydrate (and the resulting insulin rise) increases muscle carnitine retention compared to carnitine alone (Stephens et al., 2013).
Sperm motility (male fertility). Spermatozoa rely heavily on fatty acid oxidation for motility, and sperm carnitine levels are critical for this function. Epididymal fluid has some of the highest carnitine concentrations in the body. Oral L-carnitine supplementation (2-3 g daily) has been shown in multiple trials to improve sperm concentration, motility, and morphology in men with oligoasthenospermia. The mechanism is direct — providing the carnitine needed for sperm fatty acid oxidation (Lenzi et al., 2003).
Heart failure mechanisms. In heart failure, cardiac carnitine levels decline, and cardiac fatty acid oxidation becomes impaired. L-Carnitine supplementation restores cardiac carnitine content, improves cardiac fatty acid oxidation, reduces ischemic damage, and in multiple trials and meta-analyses, reduces mortality and improves symptoms. The effect is most pronounced in ischemic heart failure and post-myocardial infarction settings (DiNicolantonio et al., 2013).
TMAO production (the controversy). Gut bacteria metabolize dietary L-carnitine to trimethylamine (TMA), which is absorbed and oxidized in the liver to TMAO (trimethylamine-N-oxide). TMAO has been correlated with cardiovascular risk in some observational studies — the hypothesis being that TMAO promotes atherosclerosis. This raised concerns about L-carnitine supplementation. Subsequent work has added nuance: TMAO elevation from L-carnitine is highly variable (depends on gut microbiome composition), the TMAO-cardiovascular link may be more correlational than causal, vegans and vegetarians typically show minimal TMAO response to L-carnitine (because their gut microbiome lacks the TMA-producing organisms), and the net cardiovascular effect of L-carnitine in randomized trials remains favorable despite any TMAO increase (Koeth et al., 2013, Samulak et al., 2019).
Bioavailability and absorption. Oral L-carnitine is absorbed via active transport in the small intestine (OCTN2 transporter) with bioavailability of 14-18% — lower than for many supplements but adequate for therapeutic effects. Higher oral doses show lower fractional bioavailability as the active transport saturates. Intravenous L-carnitine achieves 100% systemic bioavailability. Muscle carnitine uptake is actively transported and can be enhanced by insulin, which is the basis for co-administration with carbohydrates. ALCAR has better brain penetration than plain L-carnitine. Propionyl-L-carnitine has better bioavailability than plain L-carnitine for vascular applications.
What L-Carnitine does NOT do. It does not directly "burn fat" in the sense of substituting for caloric deficit or exercise. It does not significantly increase metabolic rate in healthy individuals. It does not meaningfully improve muscle growth, testosterone, or growth hormone. It does not reduce appetite or cause rapid weight loss. It does not cure mitochondrial dysfunction in severe primary mitochondrial disease (though it may help in specific secondary deficiencies). It is not a stimulant or nootropic in the ALCAR-independent sense.
Interactions with other metabolic compounds. Carnitine works synergistically with CoQ10 (mitochondrial electron transport), alpha-lipoic acid (carnitine + ALA combinations have been studied in aging and cognitive applications), B-vitamins (particularly B2, which is a cofactor for the carnitine synthesis enzyme), and creatine (complementary energy systems, creatine for PCr buffer, carnitine for fatty acid oxidation). With Methylene Blue, mechanisms are complementary — both support mitochondrial function through different pathways.
Overview
L-Carnitine is a naturally occurring quaternary ammonium compound synthesized in the body from the amino acids lysine and methionine, with essential cofactor roles in fatty acid metabolism, energy production, and cellular health. Chemically classified as a conditionally essential nutrient, it is stored primarily in skeletal muscle (about 95% of total body carnitine, roughly 20 grams in an adult), with smaller pools in the liver, brain, heart, kidneys, and sperm. The body makes carnitine, but dietary intake — primarily from red meat and dairy — is the dominant source for most people. Vegans and vegetarians have measurably lower plasma carnitine levels, though this does not typically translate into overt deficiency in otherwise healthy individuals.
The fundamental biological role of L-carnitine is to shuttle long-chain fatty acids across the inner mitochondrial membrane, where they undergo beta-oxidation to produce ATP. Without adequate carnitine, long-chain fatty acids cannot enter mitochondria for energy production, and lipid metabolism grinds to a halt. This mechanism explains why carnitine is especially important for tissues with high fatty acid oxidation demands: cardiac muscle (which derives 60-90% of its energy from fat), skeletal muscle (during extended exercise), and sperm (which use fatty acid oxidation for motility). The "carnitine shuttle" is one of the core metabolic cycles in mammalian biochemistry (Longo et al., 2016).
L-Carnitine exists in several supplemental forms, and the choice matters. L-carnitine (plain L-carnitine, sometimes called L-carnitine tartrate) is the standard form — well-absorbed, supports general fatty acid metabolism, the form used in most cardiovascular and metabolic research. Acetyl-L-carnitine (ALCAR) has an acetyl group attached that allows it to cross the blood-brain barrier more effectively, giving it specific cognitive and neuroprotective applications — this is the form used in most studies of cognitive aging, mild cognitive impairment, and peripheral neuropathy. L-carnitine L-tartrate (LCLT) is a salt form with enhanced stability and is the specific form used in most exercise performance and recovery research. Propionyl-L-carnitine (PLC) has a propionyl group instead of an acetyl group and is specifically studied for peripheral artery disease and endothelial function. Glycine propionyl-L-carnitine (GPLC) is a further modification marketed for exercise performance. These are not interchangeable — research findings with one form do not automatically generalize to others (Pennisi et al., 2020).
The clinical evidence base for L-carnitine is deeper than most supplements. Cardiovascular disease — particularly heart failure, post-myocardial infarction recovery, and angina — has been the subject of multiple randomized trials and meta-analyses showing mortality reduction and symptomatic improvement. Peripheral artery disease with intermittent claudication has strong evidence for propionyl-L-carnitine specifically. Chronic fatigue and fatigue-related conditions including post-chemotherapy fatigue and HIV-associated fatigue have multiple supporting trials. Male fertility — carnitine improves sperm motility, concentration, and morphology in men with oligoasthenospermia. Cognitive aging — ALCAR has multiple trials in mild cognitive impairment and Alzheimer's disease with modest but consistent benefits. Peripheral neuropathy — ALCAR has good evidence for diabetic and chemotherapy-induced neuropathy. Hemodialysis patients — carnitine deficiency is common in dialysis, and IV L-carnitine is FDA-approved for this indication (DiNicolantonio et al., 2013, Pennisi et al., 2020).
The research peptide and performance community uses L-carnitine mostly for two broad purposes: fat loss support and exercise recovery. For fat loss, the theory is straightforward — more carnitine should improve fatty acid transport into mitochondria and therefore improve fat oxidation. The practical evidence for fat loss is modest at best; L-carnitine is not a meaningful standalone weight loss agent, but it may support fat oxidation in specific contexts (particularly in carnitine-deficient states or with appropriate training). For exercise recovery, L-carnitine L-tartrate (LCLT) has a more solid evidence base — multiple trials show reduced muscle damage markers, faster recovery between sessions, and improved recovery markers in resistance-trained individuals at 2-3 g daily (Volek et al., 2002, Spiering et al., 2008).
L-Carnitine has a complex relationship with the microbiome that has generated controversy. Dietary L-carnitine is metabolized by gut bacteria to produce TMAO (trimethylamine-N-oxide), a compound that has been associated in observational studies with increased cardiovascular risk. This finding — that the same compound used therapeutically for cardiovascular disease may also produce a putatively atherogenic metabolite — created significant debate. Subsequent work has suggested the TMAO-cardiovascular link may be more correlational than causal, that supplemental L-carnitine produces different TMAO responses than dietary sources in some populations, and that the net cardiovascular effect of L-carnitine in randomized trials remains favorable. The picture is more nuanced than initial headlines suggested (Koeth et al., 2013, Samulak et al., 2019).
L-Carnitine is not a research peptide in the sense of BPC-157 or Semax — it is a well-characterized nutritional/metabolic compound with decades of clinical use, FDA-approved forms (Carnitor IV for dialysis patients, Levocarnitine for primary and secondary carnitine deficiency), and widespread availability as a supplement. This gives the evidence base a quality and depth that most "research peptides" lack. At the same time, L-carnitine is not a miracle compound. Its effects in healthy individuals without deficiency are modest. Its role is best understood as metabolic effect — filling a specific cofactor function — rather than as a primary therapeutic intervention.
The honest framing for anyone considering L-carnitine: it has real biology, real evidence, and real clinical use. It is not going to transform your body composition or athletic performance in healthy individuals with adequate diet. It may be meaningfully useful in specific contexts: vegan/vegetarian supplementation, aging (where tissue carnitine declines), heart failure, peripheral artery disease, chronic fatigue, male fertility, cognitive aging, and dialysis patients. Beyond those contexts, use is supportive rather than transformative, and cost-benefit needs honest evaluation.
Chemical Information
IUPAC Name
(R)-3-carboxy-2-hydroxy-N,N,N-trimethylpropan-1-aminium
CAS Number
541-15-1
Molecular Formula
C7H15NO3
Molecular Mass
161.20 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
L-Carnitine has a favorable overall safety profile, but specific contraindications and cautions apply in certain medical contexts.
Absolute contraindications (do not use):
Known hypersensitivity to L-carnitine or specific formulation. Prior severe allergic reaction contraindicates repeat use of that form. Alternative forms may be tolerable; decide case-by-case with clinical input.
Active hyperactive seizure disorder. Rare case reports of seizure exacerbation with L-carnitine, particularly in epilepsy patients on valproate. In patients with active, poorly-controlled seizures, L-carnitine supplementation should not be initiated without neurology coordination. Note: This is different from the well-established use of L-carnitine AS SUPPLEMENTATION for valproate-induced carnitine deficiency, which is clinically indicated.
Untreated severe hypothyroidism. L-Carnitine may modestly reduce thyroid hormone action at tissue level. In untreated severe hypothyroidism, this could theoretically worsen symptoms. Treat hypothyroidism first; then supplementation is fine with monitoring.
Relative contraindications (caution, specific considerations):
Established atherosclerotic cardiovascular disease (nuance required). The TMAO-cardiovascular controversy has led some to question L-carnitine in ASCVD. Current evidence synthesis: net effect in randomized trials remains favorable, but patients with established ASCVD should discuss with cardiologist. Vegans/vegetarians may have metabolic advantages (less TMA-producing gut bacteria, lower TMAO response). Omnivores with established CVD should have an informed discussion about risk/benefit.
Hyperthyroidism. L-Carnitine may reduce thyroid hormone action, which could be beneficial or problematic depending on treatment strategy. Coordinate with endocrinology before initiating.
Seizure disorder (controlled). Not a strict contraindication, but close neurology follow-up appropriate. Especially if on valproate (where carnitine may actually be therapeutic) or other seizure medications.
Pregnancy (high-dose considerations). Standard doses (1-2 g daily) probably safe. Higher doses (>3 g daily) should be reserved for specific medical indications. Discuss with obstetrician.
Lactation (high-dose considerations). Similar to pregnancy. Standard doses appear safe.
Severe renal impairment requiring dialysis. This is actually typically an indication for L-carnitine (IV form FDA-approved), but dosing requires nephrology coordination.
Patients on warfarin. L-Carnitine may modestly improve warfarin effect. Monitor INR when initiating; usually no dose adjustment needed but clinical follow-up appropriate.
Specific drug interaction concerns:
Warfarin. Mild potential enhancement of anticoagulation. Monitor INR. Generally no dose adjustment needed.
Thyroid hormone replacement (levothyroxine). May modestly reduce thyroid hormone action at tissue level. Monitor TSH; separate timing by 2-3 hours.
Valproate (Depakote). Valproate causes carnitine depletion. L-Carnitine supplementation is typically indicated rather than contraindicated. Coordinate with neurology.
Pivampicillin and some other antibiotics. Can cause carnitine depletion. Supplementation may be indicated.
Statins (atorvastatin, rosuvastatin, simvastatin). No significant interaction. May be modestly supportive of muscle energy in statin-related myalgia. Well-tolerated concurrent use.
Beta-blockers. No significant interaction. Compatible for concurrent use in heart failure or hypertension.
ACE inhibitors/ARBs. No significant interaction. Compatible in heart failure or hypertension.
Metformin. No significant interaction. Compatible; both can support metabolic health.
GLP-1 agonists (semaglutide, tirzepatide, retatrutide). No significant interaction. Compatible with weight loss protocols.
Chemotherapy agents. Generally compatible but context-dependent. For chemotherapy-induced neuropathy, ALCAR may be specifically indicated. Coordinate with oncology.
Antiepileptics (other than valproate). No significant interaction with most. Monitor in epilepsy patients for any change in seizure control.
Antiretroviral therapy. No significant interaction. May support management of HIV-associated fatigue and wasting.
Insulin/sulfonylureas. No significant interaction. Monitor glucose; L-carnitine may modestly improve insulin sensitivity.
Antidepressants (SSRIs, SNRIs, TCAs). No significant interaction. Some evidence ALCAR has antidepressant properties; may be additive or beneficial.
Thyroid medications (levothyroxine, liothyronine). As above, monitor TSH; theoretical modest reduction in thyroid hormone tissue action.
Specific formulation considerations.
IV L-carnitine: Hospital/clinical setting only. Rare hypersensitivity reactions. Pre-medication not typically required.
Oral capsules/tablets: Generally well-tolerated. Standard precautions.
Sublingual/dissolvable tablets: Rare oral irritation.
Liquid formulations: Check for sugar content, flavorings, preservatives — may trigger sensitivities in specific individuals.
Genetic considerations.
OCTN2 transporter mutations. Cause primary carnitine deficiency. These patients have lifelong supplementation needs; require medical management.
CPT1, CPT2 mutations. Fatty acid oxidation defects. L-Carnitine may be part of management but complex; requires metabolic specialist.
MTHFR polymorphisms. Generally compatible with L-carnitine. Comprehensive methylation support beneficial alongside carnitine.
SLC22A5 variants. Transporter variants affect L-carnitine uptake and plasma levels. Personalized dosing may be needed for some individuals.
Age considerations.
Pediatric. Used in specific medical contexts (primary/secondary carnitine deficiency, valproate therapy, certain metabolic disorders). Not for general supplementation without indication.
Elderly. Tissue carnitine declines with age; supplementation may be more beneficial. Monitor for drug interactions (more common with polypharmacy).
Very elderly / frail. Conservative dose initiation (500 mg daily); titrate slowly.
Specific conditions warranting medical coordination before L-carnitine use:
- Active cardiovascular disease with significant atherosclerosis
- Active seizure disorder
- Hyperthyroidism (untreated or unstable)
- Severe kidney disease
- Active chemotherapy (may be indicated, but oncology coordination required)
- Valproate therapy
- Significant hepatic impairment
- Recent major surgery
- Pregnancy considerations
Stop L-carnitine and seek medical evaluation for:
- New or worsening seizures
- Significant cardiovascular symptoms (chest pain, palpitations, shortness of breath)
- Severe or persistent GI symptoms despite dose adjustment
- Allergic reaction signs
- Any unusual symptom correlating with L-carnitine use
Pre-use baseline evaluation (for high-risk individuals or advanced protocols):
- CBC
- Comprehensive metabolic panel
- Lipid panel
- TSH and thyroid panel
- For heart failure: Echo, BNP
- For fertility: Semen analysis, hormonal panel
- For PAD: Ankle-brachial index, walking distance assessment
- For neuropathy: Clinical evaluation, nerve conduction if severe
- Current medications review
Not contraindications (common misconceptions):
- Generally healthy adults (most can safely take standard doses)
- Vegetarians/vegans (may have BETTER response due to dietary deficiency)
- Athletes (compatible with training)
- Diabetes (often beneficial)
- Hypertension (no interaction with common hypertensive medications)
- Elevated cholesterol (generally beneficial for lipid profile)
Common misconceptions to dispel.
"L-Carnitine causes heart attacks." False. The TMAO observational link is weak and possibly confounded. Randomized trials in cardiac populations show benefit.
"L-Carnitine requires cycling." False. Continuous use is evidence-supported.
"High doses are more effective." False. Diminishing returns above 3 g daily for most indications.
"Vegetarians don't need carnitine." False. Vegetarians have lower carnitine levels and may benefit MORE from supplementation.
"All forms are interchangeable." False. Plain L-carnitine, ALCAR, LCLT, and PLC have form-specific evidence.
When in doubt, consult with appropriate specialist (cardiology for heart disease, endocrinology for thyroid, neurology for seizures, nephrology for kidney disease, reproductive endocrinology for fertility, geriatric or integrative medicine for older adults with multiple conditions). L-Carnitine is generally safe but benefits from informed use in specific medical contexts.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$34.99
$0.0023
1
1
vial
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
L-Carnitine 500mg/mL 30mL | vial | 30mL vial● In Stock | $34.99BEST | $0.002 |
Tracking since Apr 6, 2026 · 1 data point
Vendors Selling L-Carnitine
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View All5-Amino-1MQ
Weight LossPreclinical5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide to form 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH).
BAM15
Weight LossPreclinicalBAM15 is a small-molecule mitochondrial protonophore uncoupler that was first described in 2014 as a tool compound for dissipating proton motive force selectively across the inner mitochondrial membrane without collapsing the plasma membrane electrochemical gradient (Kenwood et al., 2014).
Exenatide
Weight LossPreclinicalGLP-1 receptor agonist used for metabolic effect and appetite regulation..
Lipo-C
Weight LossPreclinicalLipotropic compound blend injection.
Mazdutide
Weight LossPreclinicalMazdutide (also known as IBI362, Lilly compound LY3305677) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist originally discovered by Eli Lilly and exclusively licensed to Innovent Biologics in 2019 for development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan.
NAD+ Carnitine Blend
Weight LossPreclinicalNAD+ and carnitine amino blend for energy and metabolism.
View Full Dosage Guide →
Protocols, calculator & safety for L-Carnitine
Research Score
23241 PubMed studies
Quality Indicators
Data Completeness
100%Research Credibility
Well-researched compound
Quick Facts
Molecular Weight
161.20 g/mol
CAS Number
541-15-1
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
Does L-carnitine actually help with fat loss?
Modestly, at best, and not in the way marketing suggests. L-Carnitine doesn't 'burn fat' directly — it's a cofactor that transports fatty acids into mitochondria where they can be oxidized. If you're not in a caloric deficit and not exercising, adding L-carnitine won't meaningfully increase fat loss in otherwise healthy individuals. A 2016 meta-analysis of RCTs found modest weight loss (~1.3 kg average) with L-carnitine supplementation, but effects were small relative to diet and exercise (Pooyandjoo et al., 2016). Where L-carnitine CAN help with fat loss: supporting fat oxidation during fasted training, supporting metabolic rate in carnitine-deficient individuals (some vegans/vegetarians, older adults), and possibly improving exercise recovery allowing more consistent training. Realistic expectations: L-carnitine is a supportive supplement for an established fat loss effort, not a standalone fat burner. If you're looking for actual fat loss pharmacology, Semaglutide or Tirzepatide offer dramatically more impact. L-Carnitine is more relevant as metabolic support during or after these weight loss interventions.
What's the difference between L-carnitine, ALCAR, and LCLT?
These are different chemical forms with different evidence and applications. Plain L-carnitine (often as L-carnitine tartrate) is the basic form — best for general metabolic support, fat oxidation, and cardiovascular support. Acetyl-L-carnitine (ALCAR) has an acetyl group that allows better blood-brain barrier penetration — best for cognitive function, age-related cognitive decline, peripheral neuropathy, and any indication requiring CNS effects. Most cognitive aging and Alzheimer's research uses ALCAR specifically (Montgomery et al., 2003). L-carnitine L-tartrate (LCLT) is a specific salt form used in most exercise recovery research — 2 g daily LCLT reduces muscle damage markers and accelerates recovery in trained individuals (Volek et al., 2002). Propionyl-L-carnitine (PLC) supports vascular/endothelial function — specifically studied for peripheral artery disease (Hiatt et al., 2011). For most people new to L-carnitine: plain L-carnitine for general/metabolic use, ALCAR for cognitive/neurological focus, LCLT for athletic recovery, PLC for vascular indications.
Does L-carnitine increase heart disease risk through TMAO?
This is complex and the initial 2013 alarm has been tempered by subsequent research. The 2013 Koeth study showed dietary L-carnitine is metabolized by gut bacteria to TMAO, which correlated with cardiovascular disease in observational data (Koeth et al., 2013). However, follow-up research has added important nuance: (1) TMAO-CVD link may be more correlational than causal — TMAO may be a biomarker of microbiome patterns rather than a direct cause of atherosclerosis, (2) vegans/vegetarians show minimal TMAO response to L-carnitine (their gut bacteria lack TMA-producing capacity), so L-carnitine supplementation may be particularly safe for them, (3) randomized trials of L-carnitine in cardiovascular populations continue to show FAVORABLE outcomes (reduced mortality in heart failure, improved walking distance in PAD) despite any TMAO increase, (4) the net clinical effect in cardiovascular populations appears beneficial. Current thinking: Patients with established atherosclerotic cardiovascular disease should discuss L-carnitine with their cardiologist. For most individuals without established CVD, the benefits of L-carnitine in appropriate contexts likely outweigh theoretical TMAO concerns. If concerned, you can have TMAO measured (some labs offer this) and monitor individual response.
How long does it take to see results from L-carnitine?
This depends on what you're measuring. For most indications, effects are gradual. Exercise recovery (LCLT): Noticeable reduction in post-workout soreness and improved recovery within 2-4 weeks. Male fertility: Improvements in sperm parameters typically require 3-6 months (full spermatogenesis cycle is ~74 days). Cognitive support (ALCAR): Subtle improvements in mental clarity within 2-4 weeks; meaningful cognitive testing changes in MCI/AD trials often took 3-6 months. Peripheral neuropathy: Slow improvement over 6-12 months (nerve regeneration is slow). Heart failure: Functional improvements within 4-8 weeks, mortality benefits accrue over months to years in trials. Fat loss support: Modest and gradual, 4-8+ weeks. Chronic fatigue: Variable; 2-12 weeks for noticeable effects. Realistic expectations: L-Carnitine is NOT a supplement that produces dramatic immediate effects like caffeine or GLP-1 agonists. Plan to give it 2-3 months at adequate dose before concluding whether it's working. If after 12 weeks at 2-3 g daily you notice no meaningful change in your target area, it's probably not providing significant benefit for you in that context.
Should I take L-carnitine before or after my workout?
For exercise recovery benefit (the best-supported athletic indication), timing is less critical than consistent daily intake. LCLT trials showing muscle damage reduction used daily dosing, not specifically workout-timed dosing. That said, some practical strategies: Pre-workout (60-90 min before): May support fat oxidation during training; theoretical benefit for endurance activities. Post-workout: Combines with recovery meal, supports muscle substrate replenishment. Daily consistent timing (morning or split AM/PM): Simplest and most evidence-supported approach. For maximum muscle carnitine loading, research by Stephens and colleagues suggests co-ingestion with substantial carbohydrate (80+ grams) enhances insulin-driven muscle uptake (Stephens et al., 2013) — but this requires significant carbohydrate intake, not practical for everyone. Simple practical approach: 1 g with breakfast + 1 g with lunch or pre-workout. Avoid ALCAR in the late evening due to mild stimulation effects. LCLT specifically has some evidence at pre-workout (1-2 g, 60-90 min before), but daily dosing is similarly effective in most trials.
Can I take L-carnitine long-term safely?
Yes, long-term L-carnitine supplementation at standard doses (1-3 g daily) has an excellent safety profile. Clinical trials have used L-carnitine for 2+ years in cardiovascular populations with no significant safety concerns beyond mild, manageable GI effects. The fishy odor syndrome (trimethylaminuria) at high doses is cosmetic rather than harmful. There's no evidence of tolerance development, dependency, or withdrawal effects. Clinical concerns requiring attention at long-term use: (1) TMAO considerations for patients with established atherosclerotic CVD — discuss with cardiologist, (2) thyroid hormone monitoring if on replacement therapy, (3) warfarin INR monitoring, (4) standard annual health screening. For otherwise healthy individuals, continuous daily use at 1-3 g is well-supported. Some users cycle off periodically (e.g., 3 months on, 1 month off) as general conservative practice, but this is not evidence-based — it's personal preference. The FDA-approved medical uses (dialysis deficiency, primary carnitine deficiency) involve lifelong continuous use. Long-term safety data are among the best for any supplement on the market.
Does L-carnitine help with erectile function or libido?
Modest and indirect evidence. L-Carnitine and ALCAR have been studied in some erectile dysfunction contexts with mixed results. A 2004 trial in older men with sexual dysfunction showed ALCAR (2 g daily) + propionyl-L-carnitine (2 g daily) improved erectile function more than testosterone supplementation alone, particularly in older men with erectile issues. The mechanism is thought to involve vascular (via propionyl form) and mitochondrial/energetic support. However, this is NOT a primary ED treatment — medications like PT-141 specifically target sexual arousal, and PDE5 inhibitors (sildenafil, tadalafil) are the established pharmaceutical options. L-Carnitine's role in male sexual function is more supportive: improving sperm quality (well-established), possibly supporting vascular function with PLC form, and providing mitochondrial support for penile tissue energetics. For men with ED seeking supplement adjuncts: L-Carnitine 2 g + ALCAR 1 g daily alongside addressing cardiovascular risk factors, optimizing testosterone (if indicated with Enclomiphene or HCG), and using standard ED medications as needed.
What's the GlyNAC protocol and does it include L-carnitine?
GlyNAC (Glycine + N-acetylcysteine) is a specific protocol popularized by a 2021 Baylor College of Medicine study showing dramatic improvements in older adults across multiple aging biomarkers — mitochondrial function, insulin resistance, cognitive function, physical function (Kumar et al., 2021). The protocol used glycine 1.33 mmol/kg/day (~5-7 g for average adult) plus NAC 81 mg/kg/day (~5-6 g for average adult) for 16 weeks. GlyNAC does NOT directly include L-carnitine, but L-carnitine stacks mechanistically with it — glycine and NAC support glutathione synthesis and mitochondrial function from one angle; L-carnitine supports fatty acid oxidation and mitochondrial substrate delivery from another. Many longevity-focused practitioners combine them: GlyNAC protocol (full doses) + L-carnitine 2 g + ALCAR 1 g daily for comprehensive mitochondrial support. Combined mechanism: GSH precursors (glycine + NAC) + L-carnitine substrate transport + mitochondrial cofactors = broader metabolic support. Evidence for the combined protocol is mechanistic; head-to-head trials of GlyNAC + carnitine vs GlyNAC alone don't exist.
Is L-carnitine worth taking if I eat a lot of meat?
Less likely to produce dramatic effects, but may still have specific applications. Meat (especially red meat) is the primary dietary source of L-carnitine. Omnivores with regular red meat consumption typically have adequate plasma and tissue carnitine levels. Supplementation in these individuals produces more modest effects than in vegans/vegetarians (who often have lower carnitine levels) or older adults (whose tissue levels decline with age). However, even omnivores may benefit from L-carnitine supplementation in specific contexts: (1) intense athletic training where muscle carnitine may be partially depleted, (2) specific medical conditions (heart failure, PAD, male infertility, peripheral neuropathy, cognitive aging), (3) combined with ALCAR for cognitive support (requires supraphysiologic dosing to affect brain ALCAR levels), (4) during rapid weight loss or caloric restriction. For healthy meat-eating adults without specific indications, L-carnitine supplementation is probably low-yield — better to focus on other interventions (sleep, exercise, diet quality, perhaps more targeted supplements). For omnivores with specific indications (the lists above), it may still be worth trying despite adequate dietary intake. The bioavailability math: dietary sources provide 100-300 mg daily in typical omnivore diets; supplementation of 2 g daily represents 7-20x dietary intake, meaningfully above normal physiological range.
How does L-carnitine compare to creatine for exercise performance?
They serve different purposes and work through different mechanisms. Creatine supports phosphocreatine-mediated ATP resynthesis, critical for high-intensity short-duration exercise (lifting, sprinting). It's one of the most evidence-supported athletic supplements — predictably improves strength, power, and muscle mass in trained individuals. Effective dose: 3-5 g daily. L-Carnitine supports fatty acid oxidation — more relevant for endurance activities, recovery between training sessions, and metabolic flexibility. The LCLT form specifically has evidence for recovery (reduced muscle damage, faster recovery between sessions). Effective dose: 2 g daily LCLT. For most trained athletes, creatine has stronger and more immediate effects on performance outcomes (strength, power, muscle mass). L-Carnitine is more about supporting recovery and metabolic adaptation. They are not competing supplements — they're complementary. Classic stacking: 5 g creatine + 2 g LCLT daily, both with carbohydrate when possible for muscle uptake. Evidence for combined use is more extensive than for either alone. For a beginner in supplementation with limited budget, creatine is the higher-yield starting point. L-Carnitine becomes more valuable once creatine is in place and you're looking for recovery optimization or endurance support.
Research Tools
Related Compounds
View All5-Amino-1MQ
Weight LossPreclinical5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide to form 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH).
BAM15
Weight LossPreclinicalBAM15 is a small-molecule mitochondrial protonophore uncoupler that was first described in 2014 as a tool compound for dissipating proton motive force selectively across the inner mitochondrial membrane without collapsing the plasma membrane electrochemical gradient (Kenwood et al., 2014).
Exenatide
Weight LossPreclinicalGLP-1 receptor agonist used for metabolic effect and appetite regulation..
Lipo-C
Weight LossPreclinicalLipotropic compound blend injection.
Mazdutide
Weight LossPreclinicalMazdutide (also known as IBI362, Lilly compound LY3305677) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist originally discovered by Eli Lilly and exclusively licensed to Innovent Biologics in 2019 for development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan.
NAD+ Carnitine Blend
Weight LossPreclinicalNAD+ and carnitine amino blend for energy and metabolism.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.